We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 18.00 | 23.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
By Anne Steele
Prices of International stocks trading in New York closed higher on Thursday.
The BNY Mellon index of American depositary receipts rose 0.4% to 140.07. The European index increased 0.3% to 133.16, the Asian index improved 0.3% to 159.79, the Latin American index climbed 1% to 212.84 and the emerging markets index increased 0.3% to 287.26.
Pharmaceutical companies were among those trading actively.
ADRs of Teva Pharmaceutical Industries Ltd. (TEVA.TV, TEVA) ended 4.7% higher at $32.52 after Mizuho raised its rating to neutral from underperform.
ADRs of Novartis AG (NVS, NOVN.EB) rose 4.6% to $86.34 after the company said a drug that it sells for various immunology conditions reduced the risk of serious heart problems in patients who have had a heart attack and who suffer inflammation related to fat build-up in the arteries.
ADRs of Summit Therapeutics PLC (SMMT, SUMM.LN) climbed 3.7% to $11.49 after the company presented data from two early-stage clinical trials of its Duchenne muscular dystrophy drug ezutromid.
Write to Anne Steele at anne.steele@wsj.com.
(END) Dow Jones Newswires
June 22, 2017 17:29 ET (21:29 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Summit Therapeutics Chart |
1 Month Summit Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions